Bendamustine Hydrochloride 2.5mg/Ml Powder For Concentrate For Solution For Infusion
Bendamustin combi PIL WIN GB 519-M.2001 Dimensions: 150/500 mm Colour: ■ BLACK 2016-02-11 Page 1
PACKAGE LEAFLET: INFORMATION FOR THE USER
Bendamustine hydrochloride 2.5mg/ml Powder for concentrate for solution for infusion
bendamustine hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains
important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist
• This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If any of the side effects get serious talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet (see section 4).
What is in this leaflet:
1. What bendamustine is and what it is used for 4. Possible side effects
2. What you need to know before you take 5. How to store bendamustine
bendamustine 6. Contents of the pack and other information
3. How to take bendamustine
1. WHAT BENDAMUSTINE IS AND WHAT IT IS USED FOR
The name of your medicine is Bendamustine hydrochloride 2.5mg/ml Powder for concentrate for solution for infusion (referred to as bendamustine throughout this leaflet).
Bendamustine is a medicine which is used for the treatment of certain types of cancer (cytotoxic medicine).
Bendamustine is used alone (monotherapy) or in combination with other medicines for the treatment of the following forms of cancer:
• chronic lymphocytic leukaemia in cases where fludarabine combination chemotherapy is not appropriate for you,
• non-Hodgkin’s lymphomas, which had not, or only shortly, responded to prior rituximab treatment,
• Multiple myeloma in cases where high-dose chemotherapy with autologous stem cell transplantation, thalidomide or bortezomib containing therapy is not appropriate for you.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BENDAMUSTINE
Do not take bendamustine:
• if you are allergic to bendamustine hydrochloride or any of the other ingredients of this medicine (listed in section 6).
• while breastfeeding
• if you have severe liver dysfunction (damage to the functional cells of the liver)
• if you have yellowing of the skin or whites of the eyes caused by liver or blood problems (jaundice)
• if you have severely disturbed bone marrow function (bone marrow depression) and serious changes in your number of white blood cells and platelets in the blood (white blood cells and/or thrombocyte values drop to < 3,000/pl or < 75,000/pl, respectively).
• if you have had major surgical operations less than 30 days before starting treatment;
• if you have an infection, especially one accompanied by a reduction in white blood cells (leucocytopenia);
• in combination with yellow fever vaccines.
Do not take bendamustine if the above applies to you. If you are not sure, talk to your doctor or
pharmacist before taking bendamustine.
Warnings and precautions
Take special care and talk to your doctor, pharmacist or nurse before taking bendamustine:
• in case of reduced capability of the bone marrow to replace blood cells. You should have your number of white blood cells and platelets in the blood checked before starting treatment with bendamustine, before each subsequent course of treatment and in the intervals between courses of treatment.
• in case of infections. You should contact your doctor if you have signs of infection, including fever or lung symptoms.
• in cases of existing heart disease (e.g. heart attack, chest pain, severely disturbed heart rhythms).
Talk to your doctor or nurse during use of bendamustine
• in cases of nausea, vomiting. Your doctor may give you a drug to reduce nausea (antiemetic).
• in case you notice any pain in your side, blood in your urine or reduced amount of urine.
When your disease is very severe, your body may not be able to clear all the waste products from the dying cancer cells. This is called tumour lysis syndrome and can cause kidney failure and heart problems within 48 hours of the first dose of bendamustine. Your doctor will be aware of this and may give you other medicines to help prevent it.
• in case of reactions on your skin during treatment with bendamustine. The reactions may increase in severity.
• in case of severe allergic or hypersensitivity reactions. You should pay attention to infusion reactions after your first cycle of therapy.
Men receiving treatment with bendamustine are advised not to conceive a child during treatment and for up to 6 months afterwards. Before starting treatment, you should seek advice on storing sperm because of the possibility of permanent infertility.
Unintentional injection into the tissue outside blood vessels (extravasal injection) should be stopped immediately. The needle should be removed after a short aspiration. Thereafter the affected area of tissue should be cooled. The arm should be elevated. Additional treatments like the use of corticosteroids are not of clear benefit (see section 4).
Children and adolescents There is no experience in children and adolescents with bendamustine.
Other medicines and bendamustine
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, including herbal medicines. This is because bendamustine and other medicines can affect the way each other work.
If bendamustine is used in combination with medicines which inhibit the formation of blood in the bone marrow, the effect on the bone marrow may be intensified.
If bendamustine is used in combination with medicines which alter your immune response, this effect may be intensified.
Cytostatic medicines may diminish the effectiveness of live-virus vaccination. Additionally cytostatic medicines increase the risk of an infection after vaccination with live vaccines (e.g. viral vaccination).
Pregnancy, breastfeeding and fertility Pregnancy
Bendamustine can cause genetic damage and has caused malformations in animal studies.
You should not use bendamustine during pregnancy unless certainly indicated by your doctor.
In case of treatment you should use medical consultation about the risk of potential adverse effects of your therapy for the unborn child and genetic consultation is recommended.
Fertility
If you are a woman of childbearing potential you must use an effective method of contraception both before and during treatment with bendamustine. If pregnancy occurs during your treatment with bendamustine you must immediately inform your doctor and should use genetic consultation.
- If you are a man, you should avoid fathering a child during treatment with bendamustine and for up
_ to 6 months after treatment has stopped. There is a risk that treatment with bendamustine will lead
| to infertility and you may wish to seek advice on conservation of sperm before treatment starts. Breastfeeding
Bendamustine must not be administered during breastfeeding. If treatment with bendamustine is —^ necessary during lactation you must discontinue breastfeeding.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machine
No studies on the effects on the ability to drive and to use machines have been performed. Do not drive or operate machines if you experience side effects, such as dizziness or lack of coordination.
3. HOW TO TAKE BENDAMUSTINE
Bendamustine is administered into a vein over 30-60 minutes in various dosages, either alone (monotherapy) or in combination with other medicines.
Treatment should not be started if your white blood cells (leukocytes) have fallen to counts below 3,000 cells/pl and/or your blood platelets have fallen to counts below 75,000 cells/pl.
Your doctor will determine these values at regular intervals.
Chronic lymphocytic leukaemia
|
Bendamustine 100 mg per square metre of your body surface area (based on your height and weight) |
on Days 1 +2 |
|
Repeat the cycle after 4 weeks | |
|
Non-Hodqkin’s lymphomas | |
|
Bendamustine 120 mg per square metre of your body surface area (based on your height and weight) |
on Days 1 +2 |
|
Repeat the cycle after 3 weeks |
Multiple myeloma
|
Bendamustine 120 -150 mg per square metre of your body surface area (based on your height and weight) |
on Days 1 +2 |
|
Prednisone 60 mg per square metre of your body surface area (based on your height and weight) i.v. or per os. |
on Days 1 -4 |
|
Repeat the cycle after 4 weeks | |
Treatment should be terminated if white blood cell (leukocyte) and/or platelet values drop to <3,000/pl or <75,000/pl, respectively. Treatment can be continued after white blood cell values have increased to > 4,000/pl and platelet values to > 100,000/pl.
Impaired liver or kidney function
Dependent on the degree of impairment of your liver function it may be necessary to adjust your dose (by 30% in case of moderate liver dysfunction). Bendamustine should not be used if you suffer from severe liver dysfunction. No dose adjustment is necessary in case of impairment of kidney function. Your attending doctor will decide whether a dosage adjustment is necessary.
How it is administered
Treatment with bendamustine should be undertaken only by doctors experienced in tumour therapy. Your doctor will give you the exact dose of bendamustine and use the necessary precautions.
Your attending doctor will administer the solution for infusion after preparation as prescribed. The solution is administered into a vein as a short-term infusion over 30 - 60 minutes.
Duration of use
There is no time limit laid down as a general rule for treatment with bendamustine. Duration of treatment depends on disease and response to treatment.
If you are at all worried or have any questions regarding treatment with bendamustine, please speak to your doctor or nurse.
If you forget to use bendamustine
If a dose of bendamustine has been forgotten, your doctor will usually retain the normal dosage schedule.
If you stop using bendamustine
The doctor treating you will decide whether to interrupt the treatment or to change over to a different preparation.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
4. POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects may happen with this medicine.
Tissue changes (necrosis) have been observed very rarely following unintentional injection into the tissue outside blood vessels (extravascular). A burning sensation where the infusion needle is inserted may be a sign for administration outside the blood vessels. The consequence of administration in this way can be pain and poorly healing skin defects.
The dose-limiting side-effect of bendamustine is impaired bone-marrow function, which usually returns to normal after treatment. Suppressed bone marrow function increases the risk of infection.
Very common side effects (may affect more than 1 in 10 people)
Vomiting Mucosal inflammation Increased blood level of creatine Increased blood level of urea Fever Fatigue
Low counts of white blood cells (leukocytopenia)
Decrease in the red pigment of the blood (haemoglobin)
Low counts of platelets (thrombocytopenia) Infections
Feeling sick (nausea)
Common side effects (may affect up to 1 in 10 people)
Bleeding (haemorrhage)
Disturbed metabolism caused by dying cancer cells releasing their contents into the blood stream (tumor lysis syndrome)
Reduction in red blood cells which can make the skin pale and cause weakness or breathlessness (anaemia)
Low counts of neutrophils (neutropenia)
Hypersensitivity reactions such as allergic inflammation of the skin (dermatitis), nettle rash (urticaria) A rise in liver enzymes AST/ALT A rise in the enzyme alkaline phosphatase A rise in bile pigment Low potassium blood levels
Disturbed function (dysfunction) of the heart (palpitations, angina pectoris)
Disturbed heart rhythms (arrhythmia)
Low or high blood pressure (hypotension or hypertension)
Disturbed lung function Diarrhoea Constipation Sore mouth (Stomatitis)
Loss of appetite Hair loss Skin changes
Missed periods (amenorrhoea)
Pain
Insomnia Chills
Dehydration
Uncommon side effects (may affect up to 1 in 100 people)
Accumulation of fluid in the heart sac (escape of fluid into the pericardial space)
Rare side effects (may affect up to 1 in 1,000 people)
Infection of the blood (sepsis)
Severe allergic hypersensitivity reactions (anaphylactic reactions)
Signs similar to anaphylactic reactions (anaphylactoid reactions)
Drowsiness Loss of voice (aphonia)
Acute circulatory collapse Reddening of the skin (erythema)
Inflammation of the skin (dermatitis)
Itching (pruritus)
Skin rash (macular exanthema)
Excessive sweating (hyperhidrosis)
Very rare side effects (may affect up to 1 in 10,000 people)
■ Primary atypical inflammation of the lungs (pneumonia)
• Break-down of red blood cells
• Rapid decrease in blood pressure sometimes with skin reactions or rash (anaphylactic shock)
■ Disturbed sense of taste
• Altered sensations (paraesthesia)
• Malaise and pain in the limbs (peripheral neuropathy)
■ Disease of the nervous system (anticholinergic syndrome)
• Neurological disorders
• Lack of coordination (ataxia)
■ Inflammation of the brain (encephalitis)
• Increased heart rate (tachycardia)
• Heart attack, chest pain (myocardial infarct)
■ Heart failure
• Inflammation of the veins (phlebitis)
• Formation of tissue in the lungs (fibrosis of the lungs)
■ Bleeding inflammation of the gullet (haemorrhagic oesophagitis)
• Bleeding of stomach or gut
• Infertility
■ Multiple organ failure
Not known side effects (cannot be estimated from the available data) • Liver failure
There have been reports of secondary tumours (myelodysplastic syndrome, acute myeloid leukaemia (AML), bronchial carcinoma) following treatment with bendamustine. No clear relationship with bendamustine could be determined.
A small number of cases of severe skin reactions (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis) have been reported. The relationship with bendamustine is unclear.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the internet at www.mhra.aov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.
5. HOW TO STORE BENDAMUSTINE
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label carton after ‘EXP’.
_ The first two digits indicate the month and the last four digits indicate the year. The expiry date
refers to the last day of that month.
Keep the container in the outer carton to protect the content from light.
- Note on shelf-life after opening or preparing the solution
Solutions for infusions prepared according to the directions listed at the end of this leaflet are stable in polyethylene bags at room temperature / 60% relative humidity for 3.5 hours, and in a
- refrigerator they are stable for 2 days. Bendamustine contains no preservatives. The solutions
should not therefore be used after these lengths of time.
It is the responsibility of the user to maintain aseptic conditions.
—^ Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. CONTENTS OF THE PACK AND OTHER INFORMATION
What bendamustine contains:
• The active substance is bendamustine hydrochloride
1 vial contains either 25mg or 100mg of bendamustine hydrochloride.
After reconstitution 1 ml of the concentrate contains 2.5 mg bendamustine hydrochloride.
• The other ingredient is mannitol.
What Bendamustine looks like and contents of the pack:
White to off-white freeze-dried powder in an amber glass vial with a stopper and alu-cap with flip-top. Type I glass vials of 25ml or 50ml. The vials are available in packs of 5 vials. Not all pack sizes may be marketed.
The Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder Manufacturer
Zentiva, One Onslow Street, Guildford, Synthon s.r.o. Brneska 32/cp.597,
Surrey, GU1 4YS, UK. 678 01 Blansko, Czech Republic
or
Synthon Hispania SL, C/ Castello no 1,
Pol. Las Salinas, Sant Boi de Llobregat, Barcelona, 08830, Spain
This leaflet was last revised in January 2016
The following information is intended for medical or healthcare professionals only:
As with all similar cytotoxic substances, stricter safety precautions apply as far as nursing staff and doctors are concerned, due to the potentially genome-damaging and cancer-causing effect of the preparation. Avoid inhalation (breathing in) and contact with the skin and mucous membranes when handling bendamustine (wear gloves, protective clothing, and possibly a face mask). If any parts of the body become contaminated, clean them carefully with soap and water, and flush the eyes with 0.9% (isotonic) saline solution. If possible, it is advisable to work on a special safety work bench (laminar flow) with a disposable absorbent sheet that is impermeable to liquids. Contaminated articles are cytostatic waste. Please comply with national guidelines on the disposal of cytostatic material! Pregnant staff must be excluded from working with cytostatics.
The solution ready for use must be prepared by dissolving the contents of an injection vial of bendamustine exclusively in water for injections, as follows:
1. Preparation of the concentrate
- One injection vial of bendamustine containing 25 mg of bendamustine hydrochloride is first dissolved in 10 ml by shaking
- One injection vial of bendamustine containing 100 mg of bendamustine hydrochloride is first dissolved in 40 ml by shaking
2. Preparation of the solution for infusion
As soon as a clear solution is obtained (generally after 5-10 minutes), the total recommended dose of bendamustine is immediately diluted with 0.9% (isotonic) saline solution to obtain a final volume of approximately 500 ml. Bendamustine must not be diluted with other solutions for infusion or injection. Bendamustine must not be mixed in an infusion with other substances.
519-M.2001